CMET and EGFR staining showed "positive" overexpression of targeted proteins/recepotrs yet standard guidelines used to determine use of treatment on DNA genomic testing were ngeative.
Patient treated wtih both EGFR and cMET inhibitors with significant clinical response.
cMET and EGFR "POSITIVE" overexpression seen on tumor slide IHC stains, yet genetic studies negative.
Patient treated with EGFR and cMET inhibitors with significant clinical response.
New state of the art "genomic" testing is now the standard which is used to "personalize" and guide treatments. How accurate are they?
put in picture of DNA testing done
Despite "negative" MET exon deletion analysis but markedly overexpressed cMET protein in tumor cells, patient treated with cMET inhibitor with significant clinical response
Treated with an ALK inhibitor with significant clinical response despite "negative" ALK Rearrangement study, but based on markedly positive IHC overexpression of ALK protein in tumor cells